ARway Corporation (CSE:ARWY)

Intra-Cellular Therapies Income Statement

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Aug 31, 2024	Aug 31, 2023	Jul 31, 2022	Jul 31, 2021
Revenue	0.82	0.13	0.06	0.01	0.01
Revenue Growth (YoY)	546.98%	112.40%	863.46%	-33.36%	-63.90%
Cost of Revenue	0.06	-	-	-	-
Gross Profit	0.76	0.13	0.06	0.01	0.01
Selling, General & Admin	0.91	1.19	1.48	0.01	0.03
Research & Development	0.21	0.39	0.39	0.55	0.22
Operating Expenses	1.23	1.88	4.56	0.57	0.27
Operating Income	-0.46	-1.76	-4.5	-0.56	-0.26
Interest & Investment Income	-	0	0.01	-	-
EBT Excluding Unusual Items	-0.46	-1.75	-4.49	-0.56	-0.26
Gain (Loss) on Sale of Assets	-	-0	-	-	-
Asset Writedown	-	-0.67	-3.61	-	-
Other Unusual Items	-0.1	-	-	-	-
Pretax Income	-0.56	-2.43	-8.1	-0.56	-0.26
Net Income	-0.56	-2.43	-8.1	-0.56	-0.26
Net Income to Common	-0.56	-2.43	-8.1	-0.56	-0.26
Shares Outstanding (Basic)	34	29	23	-	-
Shares Outstanding (Diluted)	34	29	23	-	-
Shares Change (YoY)	17.51%	27.38%	-	-	-
EPS (Basic)	-0.02	-0.08	-0.36	-	-
EPS (Diluted)	-0.02	-0.08	-0.36	-	-
Free Cash Flow	0.01	-0.68	-1.7	-0.56	-0.24
Free Cash Flow Per Share	-	-0.02	-0.07	-	-
Gross Margin	92.83%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-56.50%	-1383.81%	-7535.38%	-9029.47%	-2768.93%
Profit Margin	-68.36%	-1913.18%	-13556.77%	-9029.47%	-2768.93%
Free Cash Flow Margin	1.30%	-532.86%	-2844.09%	-9113.34%	-2609.35%
EBITDA	-	-1.75	-4.5	-0.55	-0.24
D&A For EBITDA	-	0	0	0.01	0.01
EBIT	-0.46	-1.76	-4.5	-0.56	-0.26
EBIT Margin	-56.50%	-	-	-	-
Advertising Expenses	-	0.08	0.11	-	0

Source: S&P Global Market Intelligence. Standard template. Financial Sources.